Hemophilia treatment burden and daily life study
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have hemophilia A or B
- You are currently on preventive (prophylactic) treatment with clotting factor concentrates, either standard half-life or extended half-life
- You have been on the same type of factor (standard or extended half-life) for at least the last 6 months
- You have not developed inhibitors (antibodies that block treatment) to factor VIII or IX
- You do not have other serious long-term illnesses like cancer, severe mental health conditions, or neurological problems that could affect your feelings about treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with hemophilia about how treatments and daily life affect them. It uses your answers to improve patient-focused care and understand what challenges matter most.
This study looks at what helps or limits physical activity in adults with hemophilia who have joint damage in their legs. It may help doctors find better ways to support patients in staying active.
This study looks at chronic pain in people with severe hemophilia A. It aims to understand pain better through questionnaires and joint health checks.
This study looks at how well a newer preventive treatment for hemophilia A works in everyday life. It collects real-world information from patients to help doctors tailor clotting therapy better.
This study checks joint health and bleeding risk in people with severe hemophilia A who are taking newer factor VIII treatments or emicizumab. It uses ultrasound and blood tests to see how well these therapies protect joints.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.